Donadio Carlo, Tognotti Danika, Caponi Laura, Paolicchi Aldo
Division of Nephrology, Department of Clinical and Experimental Medicine, University of Pisa, Via Savi 10, I-56126, Pisa, Italy.
Laboratory of Clinical Pathology, Department of Translational Research, University of Pisa, Pisa, Italy.
BMC Nephrol. 2017 Feb 20;18(1):68. doi: 10.1186/s12882-017-0489-6.
Serum β-trace protein (βTP, MW 23-29 kDa) is a marker of GFR impairment in renal patients. Recent papers propose to predict residual renal function (RRF) in maintenance haemodialysis (MHD) patients from serum concentrations of βTP and other small proteins, avoiding the collection of urine. Few data are available on the removal of βTP in patients treated with dialysis membranes with different flux characteristics. The aim of this study was to evaluate the effects of haemodialysis with low-flux, high-flux and super high-flux membranes on serum concentrations of ßTP in MHD patients with null RRF.
Serum ßTP concentrations were measured before and after the first dialysis of the week in 51 MDH patients treated by low-flux (n = 24), high-flux (n = 17), or super high-flux (n = 10) membranes. The removal of β2-microglobulin (β2M, MW 11.8), cystatin C (Cys, MW 13.3), urea and creatinine was also analyzed.
Low-flux membranes did not remove βTP, β2M and Cys whose concentration increased at the end of dialysis. High-flux membrane removed more efficiently β2M and Cys than ßTP. Super high-flux membrane had the highest efficiency to remove ßTP: mean reduction ratio (RR) 53.4%, similar to β2M (59.5%), and Cys (62.0%).
In conclusion, the plasma clearance of small proteins and particularly of βTP is dependent from the permeability of the dialysis membranes Therefore, the reliability of the formulas proposed to predict RRF from serum βTP and other LMWP may be affected by the different permeability of the dialysis membranes.
血清β-微量蛋白(βTP,分子量23 - 29 kDa)是肾病患者肾小球滤过率(GFR)受损的标志物。近期文献提出,可根据血清βTP及其他小分子蛋白浓度预测维持性血液透析(MHD)患者的残余肾功能(RRF),无需收集尿液。关于不同通量特性的透析膜对βTP清除情况的数据较少。本研究旨在评估低通量、高通量和超高通量膜血液透析对RRF为零的MHD患者血清βTP浓度的影响。
对51例接受低通量(n = 24)、高通量(n = 17)或超高通量(n = 10)膜治疗的MHD患者,在每周首次透析前后测量血清βTP浓度。还分析了β2-微球蛋白(β2M,分子量11.8)、胱抑素C(Cys,分子量13.3)、尿素和肌酐的清除情况。
低通量膜不能清除βTP、β2M和Cys,透析结束时其浓度升高。高通量膜对β2M和Cys的清除效率高于βTP。超高通量膜清除βTP的效率最高:平均降低率(RR)为53.4%,与β2M(59.5%)和Cys(62.0%)相似。
总之,小分子蛋白尤其是βTP的血浆清除率取决于透析膜的通透性。因此,根据血清βTP和其他低分子量蛋白预测RRF的公式的可靠性可能会受到透析膜不同通透性的影响。